Ronald Marcus, MD

  • 4Articles
  • 14.7KReads1
  • 2005–2025Active
  • 30Collaborators
  • 46Citations2

About

Ronald Marcus, MD, is affiliated with Medical Affairs at Bristol Myers Squibb in Princeton, New Jersey. His publications from 2005 to 2025 focus on schizophrenia and schizoaffective disorders, neurology, and sexual dysfunction. He has contributed to studies on the safety and tolerability of treatments such as xanomeline, trospium chloride, and aripiprazole, as well as on adjunctive treatment strategies targeting multiple mechanisms in schizophrenia. His work appears in Psychiatrist.com, often in collaboration with co-authors including Adelaide S. Robb and Alan Breier.

Publications

JCP
Safety and Tolerability of Xanomeline and Trospium Chloride in Schizophrenia: Pooled Results From the EMERGENT Trials
Original Research

Safety and Tolerability of Xanomeline and Trospium Chloride in Schizophrenia: Pooled Results From the EMERGENT Trials

February 26, 2025

In pooled analyses, xanomeline/trospium was generally well tolerated. The most common adverse events were mild or moderate, transient, and consistent with the activity of xanomeline and trospium at muscarinic...
, , , et al
JCP
Adjunctive Treatment Targeting Multiple Mechanisms in Schizophrenia
Narrative Review

Adjunctive Treatment Targeting Multiple Mechanisms in Schizophrenia

August 19, 2024

While the pathophysiology of schizophrenia is complex, treatments with novel pharmacological actions that target these systems are of interest as adjunctive treatment for schizophrenia.
, , , et al
PCC
Article

Safety and Tolerability of Aripiprazole in the Treatment of Irritability Associated With Autistic Disorder in Pediatric Subjects (6-17 Years Old): Results From a Pooled Analysis of 2 Studies

January 6, 2011

With increasing use of atypical antipsychotics among pediatric patients, detailed information about safety and tolerability is crucial. Here, discover results from a pooled analysis of 2 studies evaluating the...
, , , et al
JCP
Original Research

Efficacy of Aripiprazole Against Hostility in Schizophrenia and Schizoaffective Disorder: Data From 5 Double-Blind Studies

November 15, 2005

, , , et al

1 Read counts for articles published before 2020 may include some non-human traffic.

2 Citation counts provided by Crossref.

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Ketamine and Psychedelics

Listen to the Podcast
The Journal of Clinical Psychiatry podcast cover with Benjamin Brody, MD

Subscribe to read
more articles

Subscribe